BioNTech posted significant advancements in its oncology pipeline during Q3 2025, reinforcing its position as a leader in immunotherapy development with promising updates on both Pumitamig and mRNA cancer therapies.

• Progress in two global registrational trials for Pumitamig, targeting lung cancer, with Phase III initiation planned for TNBC before year-end.
• Positive Phase II updates for BNT111 and Autogene cevumeran highlight the potential of mRNA therapies in low tumor burden settings, emphasizing their role in early intervention.
• Successful launch of a variant-adapted COVID-19 vaccine, with a strong financial position of over EUR 16 billion in cash and equivalents, supporting ongoing oncology initiatives.
• Integration of AI technologies showcased during the second AI Day, enhancing personalized therapy development and addressing treatment variability.
• Continued evaluation of novel combinations, including a trial for TPAM with Pumitamig, aiming for regulatory submissions and data updates by 2026.